PLX Surges on Elfabrio Growth: Buy Now?

Protalix BioTherapeutics reported Q2 2026 revenue of $19.9 million, up 27% from $15.7 million a year ago, driven by higher Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million, or $0.05 per share, versus $164,000 in the prior-year quarter.

For the first half of 2026, total revenue reached $53.6 million, more than double the $25.8 million in H1 2025, boosted by a $25 million milestone payment from Chiesi for European dosing approval. Management reaffirmed full-year revenue guidance of $78-83 million, including the milestone.

Elfabrio sales guidance for 2026 is $33-35 million, excluding milestones, reflecting continued global penetration. Elelyso sales are expected at $20-23 million, with steady demand from Pfizer and Fiocruz. The company ended the quarter with $40.7 million in cash and zero debt.

Operationally, Elfabrio received marketing authorization in South Korea in May 2026, and its U.S. patent was extended to November 2035. The PRX-115 Phase 2 RELEASE study is on track, with enrollment expected to complete by year-end and top-line results in H2 2027.

Management highlighted the growing uncontrolled gout market, now trending toward $1.6 billion annually, and noted that Krystexxa's 23% price increase signals a favorable environment for PRX-115.

Protalix's Q2 results show that its commercial strategy is working. Elfabrio, partnered with Chiesi, is gaining global traction, and the patent extension to 2035 provides long-term revenue visibility. The company's shift to profitability and debt-free balance sheet reduces risk for investors.

The bigger story is PRX-115, a potential game-changer for uncontrolled gout. With the market growing and Krystexxa's price hikes, PRX-115 could capture significant share if Phase 2 data are positive. The study's design, testing different dosing regimens, aims to differentiate on convenience and immunogenicity.

Investors should watch for enrollment completion and any interim data. A successful Phase 2 could lead to a partnership or licensing deal, providing a major catalyst. However, clinical development carries inherent risks, and the stock may remain volatile.

Overall, Protalix is executing well on its near-term commercial goals while building a promising pipeline. The balance between current revenue growth and future upside makes it an interesting speculative opportunity for biotech investors.